RenovoRx Q3 2026 net loss widens 25% year over year to $3.65 million

Bitget2026/11/05 21:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

RenovoRx’s third-quarter 2026 net loss widened 25% year over year to $3.65 million.
Revenue rose year over year to $1.07 million, driven by continued RenovoCath commercialization and expanding adoption across U.S. cancer centers.
Active commercial cancer center customers increased 24% from the second quarter to 26 at the third quarter’s end.
The Phase III TIGeR-PaC trial reached full enrollment in August 2026, with initial top-line data expected in the second half of 2027.
Full-year 2026 revenue guidance remained unchanged at $3.75 million to $4.25 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9871700) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

RenovoRx Q3 2026 net loss widens 25% year over year to $3.65 million

You may also like

Crypto prices